Archive for 2012

A new drug is approved, new questions arise. So how do we find the answers?

Fortunately, many researchers have ideas about where to look for answers, because we know that Benlysta works by reining in a type of immune cells called B cells.  B cells play an important role in the normal immune response, but when inappropriately activated in a lupus patient, they produce harmful elements that cause the damaging effects seen in SLE.  Researchers think that measuring these may provide clues to help us determine whether an individual patient is likely to respond to ...

Continue Reading →

egillespie
0

A new drug is approved. What’s next?

We finally get to ask that question about lupus, after the FDA approved Benlysta, the first new drug approved for SLE in over 50 years, in March 2011. 

Patients and researchers alike are asking questions …  Who needs to take this drug?  How is it different from the medicines that doctors were already using?  How do we know it’s going to work? How do we know that it’s going to work better than those other medications?

Continue Reading →

egillespie
0

Lifetime Risk of Adult-Onset Autoimmune Diseases

There is a recent (within the past year) article from Mayo Clinic that I’ve attached here, that I think addresses some questions about the incidence of lupus in Minnesota.  It is focused on the overall lifetime risk for development of autoimmune diseases, including SLE.

“The Lifetime Risk of Adult-Onset Rheumatoid Arthritis and Other Inflammatory Autoimmune Rheumatic Diseases”

Article published in:
Arthritis & Rheumatism
Vol. 63, No. 3
March 2011

Continue Reading →

egillespie
0
Page 3 of 3 123

# #